Esperion Therapeutics (ESPR) Reiterated at Buy by Needham & Company, Expect Nexletol/Nexlizet to Deliver Important Sales Growth, but Focus Remains on CLEAR Trial Results
Tweet Send to a Friend
Needham & Company analyst Serge Belanger reiterated a Buy rating and $12.00 price target on Esperion Therapeutics (NASDAQ: ESPR), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
